Your browser doesn't support javascript.
loading
Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab.
Heinrichs, Amélie; Dessars, Barbara; El Housni, Hakim; Pluymers, Wim; Peeters, Karen; Benghiat, Fleur S; Heimann, Pierre.
Affiliation
  • Heinrichs A; Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium. Electronic address: Amelie.Heinrichs@erasme.ulb.ac.be.
  • Dessars B; Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium. Electronic address: barbara.dessars@ghdc.be.
  • El Housni H; Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium. Electronic address: Hakim.ElHousni@erasme.ulb.ac.be.
  • Pluymers W; Novartis Pharma SA/NV, Medialaan 40, B-1800, Vilvoorde, Belgium. Electronic address: wim.pluymers@novartis.com.
  • Peeters K; Novartis Pharma SA/NV, Medialaan 40, B-1800, Vilvoorde, Belgium. Electronic address: karen.peeters@novartis.com.
  • Benghiat FS; Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium. Electronic address: Samantha.Benghiat@erasme.ulb.ac.be.
  • Heimann P; Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium. Electronic address: Pierre.Heimann@erasme.ulb.ac.be.
Leuk Res ; 67: 27-31, 2018 04.
Article in En | MEDLINE | ID: mdl-29425962
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Withholding Treatment / Imatinib Mesylate / Laboratories / Antineoplastic Agents Type of study: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Leuk Res Year: 2018 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Withholding Treatment / Imatinib Mesylate / Laboratories / Antineoplastic Agents Type of study: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Leuk Res Year: 2018 Document type: Article